Treatment of metastatic prostate cancer

Abstract

The authors review the current therapeutic approaches and consider the many remaining questions and challenges facing clinicians involved in the care of men with metastatic prostate cancer.

Metastasis to Paranasal Sinuses from Carcinoma of Prostate: Report of a Case and Review of the Literature

“…The head and neck are rare locations for metastasis, and it occurs more frequently in the brain, dura, and lymph nodes [ 11 ]. The treatment may be hormone therapy, chemotherapy, radioisotopes, and radiotherapy [ 12 ].…”

A Qualitative Study Exploring Models of Supportive Care in Men and Their Partners/Caregivers Affected by Metastatic Prostate Cancer

“…Currently, there are more than 330,000 men living with prostate cancer in the UK, with more than 44,000 being diagnosed every year (Prostate Cancer UK, 2016). Newer palliative therapies for metastatic prostate cancer have improved survival rates (Gilson, Manickavasagar, & Chowdhury, 2015) and therefore, larger numbers of men are requiring on-going supportive care. The treatment for metastatic prostate cancer disease aims to reduce systematic testosterone levels, which can be achieved surgically or by chemical castration (also known as androgen deprivation therapy (ADT) or androgen suppression therapy) (NICE, 2014).…”

Will chemotherapy change the management of prostate cancer?

“…These have largely been studied in metastatic castrate refractory prostate cancer (mCRPC) and have prolonged survival but in each case by less than 6 months [1]. The initial treatment of prostate cancer has not significantly changed since Huggins and Hodges first demonstrated the effects of castration and androgen deprivation which remains the mainstay of systemic treatment.…”